The United States Government has acquired other 500,000 dose of the Evus hero, from AstraZeneca, which increases the initial agreement with the North American Executive, which has already established an initial purchase of 700,000 doses of the therapy.
Evusheld has been shown to be effective, according to studies from the Oxford University, from the United Kingdom, and Washington, from the United States, for covid-19 in patients with compromised immunity.
This therapy is already licensed for emergency use in several countries. Evusheld is a combination of two monoclonal antibodies long-lasting, tixagemivab and cylgamivad, which has shown neutralizing activity once morest omicron and all other variants.
Its use has shown good results in oncological, transplant, chronic elderly, multi-pathological patients, among others, with compromised immunity. Vulnerable patients who only with vaccination fail to reach sufficient levels of protection to “Normalize” your activity or even maintain strict confinements to minimize the risk of contagion.
More than 2% of the world’s population is at risk of an inadequate response to vaccines once morest covid-19, so you can benefit from Evusheld for the prior prophylaxis of this coronavirus pathology. It is given as an intramuscular dose of 150 mg of tixagemivad and 150 mg of cilgavimad, in two separate consecutive injections.
The data reflected in three independent studies give Evusheld the confidence to avoid the disease in people with immunity problems. For this reason, this drug has been welcomed with hope by associations of patients suffering from immunity problems, to whom the contagion of covid-19 can cause serious consequences.
.
